These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

453 related items for PubMed ID: 20707757

  • 1. Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
    Yau T, Pang R, Chan P, Poon RT.
    Expert Opin Pharmacother; 2010 Sep; 11(13):2187-98. PubMed ID: 20707757
    [Abstract] [Full Text] [Related]

  • 2. Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report.
    Curtit E, Thiery-Vuillemin A, Nguyen T, Heyd B, Pivot X, Di Martino V, Borg C.
    J Clin Oncol; 2011 Apr 20; 29(12):e330-2. PubMed ID: 21263091
    [No Abstract] [Full Text] [Related]

  • 3. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials.
    Zhang T, Ding X, Wei D, Cheng P, Su X, Liu H, Wang D, Gao H.
    Anticancer Drugs; 2010 Mar 20; 21(3):326-32. PubMed ID: 20016366
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Novel molecular therapies in hepatocellular carcinoma.
    Faivre S, Bouattour M, Raymond E.
    Liver Int; 2011 Jan 20; 31 Suppl 1():151-60. PubMed ID: 21205154
    [Abstract] [Full Text] [Related]

  • 6. Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone.
    Kim HY, Park JW.
    Dig Dis; 2011 Jan 20; 29(3):303-9. PubMed ID: 21829021
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
    Wörns MA, Weinmann A, Pfingst K, Schulte-Sasse C, Messow CM, Schulze-Bergkamen H, Teufel A, Schuchmann M, Kanzler S, Düber C, Otto G, Galle PR.
    J Clin Gastroenterol; 2009 Jan 20; 43(5):489-95. PubMed ID: 19247201
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Treating hepatocellular carcinoma with sorafenib in liver transplant patients: an initial experience.
    Saidi RF, Shah SA, Rawson AP, Grossman S, Piperdi B, Bozorgzadeh A.
    Transplant Proc; 2010 Dec 20; 42(10):4582-4. PubMed ID: 21168742
    [Abstract] [Full Text] [Related]

  • 14. Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis.
    Schütte K, Zimmermann L, Bornschein J, Csepregi A, Rühl R, Ricke J, Malfertheiner P.
    Digestion; 2011 Dec 20; 83(4):275-82. PubMed ID: 21282952
    [Abstract] [Full Text] [Related]

  • 15. Clinical management and case reports for the treatment of hepatocellular carcinoma with sorafenib.
    Frenette CT, Frederick RT, Gish RG.
    J Clin Gastroenterol; 2011 Sep 20; 45(8):733-7. PubMed ID: 20930642
    [Abstract] [Full Text] [Related]

  • 16. Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy.
    O'Neil BH, Venook AP.
    Oncologist; 2007 Dec 20; 12(12):1425-32. PubMed ID: 18165619
    [Abstract] [Full Text] [Related]

  • 17. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy.
    Saab S, McTigue M, Finn RS, Busuttil RW.
    Exp Clin Transplant; 2010 Dec 20; 8(4):307-13. PubMed ID: 21143097
    [Abstract] [Full Text] [Related]

  • 18. The present and the future landscape of treatment of advanced hepatocellular carcinoma.
    Rimassa L, Santoro A.
    Dig Liver Dis; 2010 Jul 20; 42 Suppl 3():S273-80. PubMed ID: 20547314
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of sorafenib, molecular targeting drug, for advanced hepatocellular carcinoma.
    Kuzuya T, Tsuchiya K, Izumi N.
    Gan To Kagaku Ryoho; 2010 Oct 20; 37(10):1883-86. PubMed ID: 21069944
    [No Abstract] [Full Text] [Related]

  • 20. Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma.
    Miyahara K, Nouso K, Tomoda T, Kobayashi S, Hagihara H, Kuwaki K, Toshimori J, Onishi H, Ikeda F, Miyake Y, Nakamura S, Shiraha H, Takaki A, Yamamoto K.
    J Gastroenterol Hepatol; 2011 Nov 20; 26(11):1604-11. PubMed ID: 22011296
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.